DOP2006000241A - Composiciones farmacéuticas sólidas que contienen pregabalina - Google Patents

Composiciones farmacéuticas sólidas que contienen pregabalina

Info

Publication number
DOP2006000241A
DOP2006000241A DO2006000241A DO2006000241A DOP2006000241A DO P2006000241 A DOP2006000241 A DO P2006000241A DO 2006000241 A DO2006000241 A DO 2006000241A DO 2006000241 A DO2006000241 A DO 2006000241A DO P2006000241 A DOP2006000241 A DO P2006000241A
Authority
DO
Dominican Republic
Prior art keywords
solid pharmaceutical
pregabaline
pharmaceutical compositions
compositions containing
examples
Prior art date
Application number
DO2006000241A
Other languages
English (en)
Inventor
Howard Norman Bockbrader
Yun Hyung Cho
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2006000241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2006000241A publication Critical patent/DOP2006000241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica sólida que contiene pregabalina. La composición incluye un agente que forma una matriz y un agente de hinchamiento y es adecuada para la administración oral una vez al día. Los ejemplos de agentes que forman una matriz incluyen mezclas de poli(acetato de vinilo) y polivinilpirrolidona, y los ejemplos de agentes de hinchamiento incluyen polímeros reticulados de polivinilpirrolidona.
DO2006000241A 2005-11-02 2006-11-01 Composiciones farmacéuticas sólidas que contienen pregabalina DOP2006000241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73258905P 2005-11-02 2005-11-02

Publications (1)

Publication Number Publication Date
DOP2006000241A true DOP2006000241A (es) 2007-05-31

Family

ID=37965070

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000241A DOP2006000241A (es) 2005-11-02 2006-11-01 Composiciones farmacéuticas sólidas que contienen pregabalina

Country Status (34)

Country Link
US (11) US20070269511A1 (es)
EP (1) EP1945186B1 (es)
JP (1) JP4334610B2 (es)
KR (1) KR101012533B1 (es)
CN (1) CN101330907B (es)
AP (1) AP2008004465A0 (es)
AR (1) AR058175A1 (es)
AU (1) AU2006310217B2 (es)
BR (1) BRPI0618211B8 (es)
CA (1) CA2628200C (es)
CR (1) CR9950A (es)
DK (1) DK1945186T3 (es)
DO (1) DOP2006000241A (es)
EA (1) EA012377B1 (es)
EC (1) ECSP088422A (es)
ES (1) ES2449231T3 (es)
GT (1) GT200600474A (es)
HK (1) HK1126394A1 (es)
IL (1) IL190827A (es)
MA (1) MA30135B1 (es)
ME (1) ME00482B (es)
NL (1) NL2000281C2 (es)
NO (1) NO20081816L (es)
NZ (1) NZ567414A (es)
PE (1) PE20070693A1 (es)
PL (1) PL1945186T3 (es)
PT (1) PT1945186E (es)
RS (1) RS20080181A (es)
SI (1) SI1945186T1 (es)
TN (1) TNSN08194A1 (es)
TW (1) TWI330080B (es)
UY (1) UY29890A1 (es)
WO (1) WO2007052125A2 (es)
ZA (1) ZA200803115B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
WO2009049642A1 (en) * 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2242737A1 (en) * 2007-12-21 2010-10-27 Synthon B.V. Pregabalin salts
EA019794B1 (ru) * 2008-07-09 2014-06-30 Мелальюка, Инк. Комплекс для доставки млекопитающему минерала
CA2765172A1 (en) 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
MX2012009798A (es) * 2010-02-24 2012-09-12 Pfizer Composiciones veterinarias.
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
AU2011276170B2 (en) * 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
US20130280324A1 (en) * 2010-09-17 2013-10-24 Panacea Biotec Ltd. Sustained release pharmaceutical compositions comprising pregabalin
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
EP2736499B1 (en) * 2011-07-26 2016-05-11 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
US9393205B2 (en) 2012-01-30 2016-07-19 Sun Pharmaceutical Industries Limited Gastroretentive tablets
US20140378545A1 (en) * 2012-01-30 2014-12-25 Ranbaxy Laboratories Limited Pregabalin gr tablets
CN102743357A (zh) * 2012-06-26 2012-10-24 严轶东 一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
IN2015DN04161A (es) 2012-10-16 2015-10-16 Ranbaxy Lab Ltd
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
EP3099288A1 (en) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2016062182A1 (zh) * 2014-10-24 2016-04-28 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
CN104906064B (zh) * 2015-05-15 2017-12-22 中国药科大学 一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) * 2015-05-20 2017-08-29 Altera Corporation Pipelined cascaded digital signal processing structures and methods
CA2953225A1 (en) * 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
CN104840443B (zh) * 2015-05-27 2018-04-27 齐鲁制药有限公司 含活性成分普瑞巴林的药物组合物
CN109475510B (zh) * 2016-07-17 2023-03-10 Mapi医药公司 普瑞巴林的延长释放剂型
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
JP7138666B2 (ja) * 2018-01-24 2022-09-16 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
CN110585153A (zh) * 2018-06-13 2019-12-20 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111741748B (zh) * 2018-06-13 2022-09-23 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
WO2020006372A1 (en) * 2018-06-28 2020-01-02 Mylan Inc. Pregabalin extended-release fomulations
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
DK3760190T3 (da) 2019-07-03 2023-09-04 Alvogen Inc Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
TW202300138A (zh) * 2021-03-17 2023-01-01 大陸商上海博志研新藥物技術有限公司 拉考沙胺藥物組合物、其製備方法及應用
CN113577036B (zh) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 一种普瑞巴林胃漂浮缓释片及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124363B1 (en) 1983-05-02 1990-12-19 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
AU8699298A (en) 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AU769038B2 (en) 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
BR9910508B1 (pt) 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
TR200400953T4 (tr) * 2000-01-27 2004-07-21 Warner Lambert Company Pregabalinin asimetrik sentezi.
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
PT1289364E (pt) 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
KR20030013460A (ko) 2000-06-23 2003-02-14 테바 파마슈티컬 인더스트리즈 리미티드 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2007505149A (ja) * 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
US20050163850A1 (en) 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa

Also Published As

Publication number Publication date
EA200800931A1 (ru) 2008-10-30
EP1945186A2 (en) 2008-07-23
ES2449231T3 (es) 2014-03-18
EA012377B1 (ru) 2009-10-30
TWI330080B (en) 2010-09-11
NO20081816L (no) 2008-05-08
EP1945186B1 (en) 2014-01-22
CA2628200C (en) 2011-01-25
PT1945186E (pt) 2014-03-06
KR101012533B1 (ko) 2011-02-07
US20130303618A1 (en) 2013-11-14
AP2008004465A0 (en) 2008-06-30
RS20080181A (en) 2009-07-15
WO2007052125A2 (en) 2007-05-10
TNSN08194A1 (fr) 2009-10-30
ECSP088422A (es) 2008-05-30
UY29890A1 (es) 2007-05-31
US20070269511A1 (en) 2007-11-22
PE20070693A1 (es) 2007-08-11
WO2007052125A3 (en) 2007-09-07
KR20080059427A (ko) 2008-06-27
IL190827A0 (en) 2008-12-29
US20150094371A1 (en) 2015-04-02
NZ567414A (en) 2011-09-30
NL2000281A1 (nl) 2007-05-03
US9144559B2 (en) 2015-09-29
HK1126394A1 (en) 2009-09-04
US20140163103A1 (en) 2014-06-12
AU2006310217A1 (en) 2007-05-10
CN101330907A (zh) 2008-12-24
US8945620B2 (en) 2015-02-03
DK1945186T3 (en) 2014-03-17
IL190827A (en) 2012-08-30
MA30135B1 (fr) 2009-01-02
NL2000281C2 (nl) 2007-08-07
US20130102675A1 (en) 2013-04-25
US20120029081A1 (en) 2012-02-02
US20160250147A1 (en) 2016-09-01
TW200803831A (en) 2008-01-16
AU2006310217B2 (en) 2012-08-16
US20170136125A1 (en) 2017-05-18
BRPI0618211B1 (pt) 2020-11-17
BRPI0618211A2 (pt) 2011-08-23
PL1945186T3 (pl) 2014-05-30
JP2009514847A (ja) 2009-04-09
US20170348420A1 (en) 2017-12-07
CN101330907B (zh) 2012-08-29
US10022447B2 (en) 2018-07-17
CA2628200A1 (en) 2007-05-10
AR058175A1 (es) 2008-01-23
ZA200803115B (en) 2009-09-30
SI1945186T1 (sl) 2014-03-31
US20120232149A1 (en) 2012-09-13
GT200600474A (es) 2007-06-08
CR9950A (es) 2008-05-28
ME00482B (me) 2011-10-10
US20150352066A1 (en) 2015-12-10
BRPI0618211B8 (pt) 2021-05-25
JP4334610B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
ECSP088422A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
PA8625001A1 (es) Composiciones de pelicula
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
UY27727A1 (es) Nueva composicion farmacéutica-
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
UY28457A1 (es) Nueva composición
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
EA200501262A1 (ru) Композиция с пролонгированным высвобождением венлафаксина